Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study

NEXT STORY
Enosi Life Sciences Appoints Biotech, Pharma and Venture Capital Veteran Dr. James N. Woody as Executive Chairman
PREV STORY
Non-Invasive Prenatal Testing Market to Reach $10.88 Billion by 2027; Technological Intervention has Played a Massive Role in Market Growth, says Fortune Business Insights™
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (‘CLEAR’ and ‘CLASSIC’) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (‘Avacopan’)

-- Oral presentation at the American Society of Nephrology (ASN) Kidney Week 2016 to ...

author_avatar
NASDAQ Market News

SIGA Technologies to Ring the Nasdaq Opening Bell on Friday, September 14, 2018

NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), ...

author_avatar
NASDAQ Market News

Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine (NEJM)

author_avatar
NASDAQ Market News